At present, the concentration is not high as China's industrial economic structure is a common fault, the same is true of the pharmaceutical industry.  The pharmaceutical industry "twelfth five-year" development planning, made clear that the current pharmaceutical industry industry concentration degree is low, enterprises, small and scattered problems still outstanding, therefore we should encourage strong enterprises implement the merger and reorganization.

M&a tide was repeated with the pharmaceutical industry, and conformity effect appeared continuously, policy combination strength to promote the pharmaceutical industry also great integration of historical opportunity, most people in the industry is generally believed that "bigger and stronger" will become the pharmaceutical industry restructuring mergers and acquisitions in the future a period of time the persistence of the theme,  has taken the pharmaceutical industry as a strategic industry in our country, but the pharmaceutical industry output value proportion of GDP is still small,  and the "bigger and stronger" will also be promoted industrial concentration.

In industrial concentration constant poly nuclear radiation multipolar development and industry under the situation of m&a has become the industry restructuring and to focus on the most efficient, most mainstream path, more become the enterprise scale, the most important way to enhance competitiveness.

Nearly two years of the pharmaceutical industry mergers and acquisitions blustery, by integrating become bigger and stronger, and has become the theme of the industry. "Twelfth five-year" period,  the pharmaceutical industry consolidation denotative opportunities exist not only, more industry profitability turnaround endogenous type opportunities exist,  the pharmaceutical industry's m&a gradually into the rush hour.

Despite the merger, acquisition and reorganization is the enterprise in competition is a common strategy in the process of way, but with foreign research institutions on the global m&a case survey found that nearly two-thirds of m&a failed, only nearly a quarter of m&a success.

So relative to the distinct themes and pertinence in the field of mergers and acquisitions, the whole industry chain of mergers and acquisitions mode is one of the important direction of big carriers m&a.  Through mergers and acquisitions to expand new areas and new direction,  even is the upstream and downstream or technical mergers and acquisitions,  has become a drug firms "large" open plan of mergers and acquisitions.

But it is important to note that although there are a number of pharmaceutical companies now expanding type of mergers and acquisitions, claims to be a comprehensive pharmaceutical enterprise, but often also emphasized to be a leader of market segment. Some growing competitiveness highly appreciates the pharmaceutical listed companies have launched a denotative expansion, diversification, and then subdivide the market profit.